Evidence map›Paper›PMID 29768720›Full record

ArticleChemMedChem2018

Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.

Chunhui Li, Peng Teng, Zhong Peng, Peng Sang, Xingmin Sun, Jianfeng Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. A unique class of ZnNature communications · 2022
    Article
  2. Article
  3. Article
  4. Vetiver andJournal of advanced research · 2019
    Article
  5. Recent advances in the treatment ofInfection and drug resistance · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chunhui LiDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL, 33612, USA.
Peng TengDepartment of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA.ORCID 0000-0002-7412-9646
Zhong PengDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL, 33612, USA.
Peng SangDepartment of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA.
Xingmin SunDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL, 33612, USA.
Jianfeng CaiDepartment of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA.ORCID 0000-0003-3106-3306

Funding

Multivalent vaccines against Clostridium difficile infectionR01AI132711 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI Xingmin Sun, Shifeng Wang · 2017 to 2026
$3.3M
Requesting HPLC for the project of "Alpha-AApeptides as a Novel Class of Antimicrobial Biomaterials"R01GM112652 · NIGMS · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG · 2015 to 2019
$1.5M
Signaling pathway of TNF-alpha production and Clostridium difficile infection (CDK01DK092352 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2012 to 2016
$470k
Multivalent Bacillus mucosal vaccines against Clostridium difficile infectionR21AI113470 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2015 to 2016
$438k
The role of tumor progression locus 2 (TPL2) in the pathogenesis of Clostridium difficile infection (CDI)R03DK112004 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI SUN, XINGMIN · 2017 to 2018
$154k
NIAID NIH HHS R01 AI132711NIAID NIH HHS R21 AI113470NIDDK NIH HHS K01 DK092352NIDDK NIH HHS R03 DK112004NIGMS NIH HHS R01 GM112652
6 · The paper itself

Abstract

Clostridium difficile infection (CDI) symptoms range from diarrhea to severe toxic megacolon and even death. Due to its rapid acquisition of resistance, C. difficile is listed as an urgent antibiotic-resistant threat, and has surpassed methicillin-resistant Staphylococcus aureus (MRSA) as the most common hospital-acquired infection in the USA. To combat this pathogen, a new structural class of pseudo-peptides that exhibit antimicrobial activities could play an important role. Herein we report a set of bis-cyclic guanidine compounds that show potent antibacterial activity against C. difficile with decent selectivity. Eight compounds showed high in vitro potency against C. difficile UK6 with MIC values of 1.0 μg mL

Indexed as

AnimalsAnti-Bacterial AgentsClostridioides difficileClostridium InfectionsFemaleGuanidinesHumansMice, Inbred C57BLSmall Molecule LibrariesAnti-Bacterial AgentsGuanidinesSmall Molecule Librariesantibioticsbis-cyclic guanidinesClostridium difficiledrug resistance

Identifiers

PMID29768720
PMCPMC6121702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.